Changes in immune parameters such as CD4+, CD8+ T-cells, NK, and myeloid derived suppressor cell populations have been suggested to be biomarkers for lung cancer and non-Hodgkin’s lymphoma treatment responses [38,39]. Here, CD4 is linked to lung cancer.